Xiujin Shi

Dr. Xiujin Shi


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2021 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
XSXiujin Shi
Xiujin Shi
YZYunnan Zhang
Yunnan Zhang
YZYi Zhang
Yi Zhang
RZRu Zhang
Ru Zhang
BLBaidi Lin
Baidi Lin
YLYang Lin
Yang Lin
Background: The clinical benefits of cytochrome P450 (CYP) 2C19 genotype-guided antiplatelet therapy in Asians remain unclear. In this study, we aimed to investigate the clinical outcomes of pharmacogenomic antiplatelet therapy in Chinese patients.Methods: Patients with acute coronary syndrome planning to undergo percutaneous coronary intervention were eligible for this study and were randomly divided into a genotype-guided treatment (GT) group and routine treatment (RT) group, with a ratio of 2:1. Patients in the GT group underwent CYP2C19 genotyping (*2 and *3 alleles), and the results were considered in selecting P2Y12 receptor inhibitors. Patients in the RT group were treated with P2Y12 receptor inhibitors according to their clinical characteristics. The primary endpoint was a composite of major adverse cardiovascular or cerebrovascular events (MACCE). The secondary endpoint was significant bleeding events.Results: Finally, 301 patients were enrolled; 75.1% were men and the mean age was 59.7 ± 9.8 years. In total, 281 patients completed the follow-up procedure. The primary endpoint occurred in 16 patients, 6 patients in the GT group and 10 in the RT group. The GT group showed lower MACCE rates than the RT group (6/189 vs. 10/92, 3.2 vs. 10.9%, hazard ratio: 0.281, 95% confidence interval: 0.102–0.773, P = 0.009). There was no statistically difference in significant bleeding events between the GT and RT groups (4.2 vs. 3.3%, hazard ratio: 1.315, 95% confidence interval: 0.349–4.956, P = 0.685).Conclusion: Personalized antiplatelet therapy that is based on CYP2C19 genotypes could decrease MACCE within a 12-month period in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention.Clinical Trial Registration:http://www.chictr.org.cn, identifier: ChiCTR2000034352.

13 March 2023 in Global Heart
Verified
Journal Article
Open access
PDF file
JHJialun Han
Jialun Han
YZYi Zhang
Yi Zhang
XSXiujin Shi
Xiujin Shi
BLBaidi Lin
Baidi Lin
YZYunnan Zhang
Yunnan Zhang
YLYang Lin
Yang Lin
It remains controversial whether to extend the course of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI). We conducted a study to investigate the benefits and risks of applying DAPT for different durations after PCI in acute coronary syndromes (ACS) patients in China. What’s more, we explored the efficacy of extended DAPT regimen based on ticagrelor. This single-center prospective cohort study used data obtained from the PHARM-ACS Patient Registration Database. We included all patients who were discharged between April and December 2018. All patients had at least 18 months of follow-up. Patients were divided into two groups according to the duration of DAPT: a 1-year group and a >1-year group. Potential bias between the two groups was adjusted for by propensity score matching using logistic regression. The primary outcomes were major adverse cardiovascular and cerebrovascular events (MACCE), defined as a composite of death, myocardial infarction, and stroke occurring from 12 months after discharge to follow-up visit. The safety endpoint was any significant bleeding event (BARC ≥ 2). Of 3,205 patients enrolled, 2,201 (68.67%) had DAPT prolonged beyond one year. A total of 2,000 patients were successfully propensity score-matched; patients who received DAPT > 1-year (n = 1000), compared with DAPT = 1-year patients (n = 1000), had a similar risk of MACCE (adjusted HR 0.23, 95% CI 0.05–1.10) and significant bleeding events (adjusted HR 0.63, 95% CI 0.32–1.24). The DAPT > 1-year group had a higher risk of revascularization (adjusted HR 3.36, 95% CI 1.64–6.87). Prolonged DAPT may not be of sufficient benefit to ACS patients within 12–18 months after the index PCI to offset the increased risk of significant bleeding events.

20 July 2026
Verified
Book Chapter
Open access
PDF file
MZMuhan Zheng
Muhan Zheng
Zhaohui BaiZhaohui Bai
Zhaohui Bai
WHWenxuan Hu
Wenxuan Hu
XHXiaojuan Hu
Xiaojuan Hu
MBMengyi Bie
Mengyi Bie
XSXiujin Shi
Xiujin Shi
Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a systemic cardiometabolic disorder rather than an isolated liver condition. Hypertension is one of the most common and clinically important comorbidities in patients with MASLD, contributing to cardiovascular, renal, and potentially liver-related disease burden. This chapter summarizes recent advances in the pathophysiological and clinical links between hypertension and MASLD. Shared mechanisms include insulin resistance, visceral adiposity, adipose tissue dysfunction, renin-angiotensin-aldosterone system activation, sympathetic nervous system activation, oxidative stress, chronic inflammation, endothelial dysfunction, and gut-liver axis dysregulation. These pathways may jointly promote hepatic steatosis, metabolic dysfunction-associated steatohepatitis (MASH) progression, liver fibrosis, blood pressure elevation, vascular injury, and cardiovascular risk. Clinical evidence from studies using earlier nonalcoholic fatty liver disease (NAFLD) definitions, together with emerging MASLD-based evidence, suggests a close relationship between hypertension and MASLD, with some studies also supporting a potential bidirectional association, although causality remains difficult to establish. Hypertension has also been associated with liver stiffness progression, histological fibrosis progression, and adverse clinical outcomes in MASLD. Risk stratification should therefore integrate liver, cardiovascular, renal, and metabolic assessment, including non-invasive fibrosis evaluation and global cardiovascular risk management. Lifestyle intervention, metabolic risk control, and appropriate blood pressure management remain central to clinical care. Future research should clarify causal pathways, define optimal screening strategies, and determine whether antihypertensive treatment alone can improve hepatic steatosis, MASH, or liver fibrosis beyond its established cardiovascular and renal benefits.